263257-15-4

Basic information

• Product Name: Tetrahydropyran-4-ylmagnesium chloride, 0.50 M in THF
• Synonyms: Tetrahydropyran-4-ylmagnesium chloride, 0.50 M in THF;Tetrahydropyran-4-ylmagnesium chloride, 0.50 M in 2-MeTHF;Tetrahydropyran-4-ylmagnesium chloride
• CAS NO: 263257-15-4
• Molecular Formula: C₅H₉ClMgO
• Molecular Weight: 144.89
• Mol File: 263257-15-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Tetrahydropyran-4-ylmagnesium chloride, 0.50 M in THF(CAS DataBase Reference)
• NIST Chemistry Reference: Tetrahydropyran-4-ylmagnesium chloride, 0.50 M in THF(263257-15-4)
• EPA Substance Registry System: Tetrahydropyran-4-ylmagnesium chloride, 0.50 M in THF(263257-15-4)

Safety Data

• Hazardous Substances Data: 263257-15-4(Hazardous Substances Data)

Upstream product

• 1768-64-5 4-chlorotetrahydro-2H-pyran 
• 7439-95-4 magnesium 
• 106-93-4 ethylene dibromide 
• 1068-55-9 isopropylmagnesium chloride 

Downstream Products

• 949089-07-0 (2-{[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino]-methyl}-4-trifluoromethyl-phenyl)-(tetrahydro-pyran-4-yl)-methanol 
• 639468-72-7 phenyl(tetrahydro-2H-pyran-4-yl)methanone 
• 1431139-70-6 C₂₀H₃₁NO₃ 
• 852237-39-9 [4-(phenylmethyl)morpholin-2-yl](tetrahydro-2H-pyran-4-yl)methanone 
• 852237-41-3 (S)-(4-benzylmorpholin-2-yl)(tetrahydro-2H-pyran-4-yl)methanone 
• 107813-74-1 [4-(quinolin-2-ylmethoxy)-phenyl]-(tetrahydro-pyran-4-yl)-methanol 

Relevant articles and documents

OXYSTEROLS AND METHODS OF USE THEREOF

Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

BROMODOMAIN INHIBITORS AND USES THEREOF

The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.

3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS

In one aspect, the invention relates to compounds of formula I: where R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In a

Practical synthesis of chiral 2-morpholine: (4-Benzylmorpholin-2-(s)-yl)- (tetrahydropyran-4-yl) Methanone mesylate, a useful pharmaceutical intermediate

A commercial synthesis was developed for the production of (4-benzylmorpholin-2-(S)-yl)-(tetrahydropyran-4-yl) methanone mesylate, la, a key starting material for a phase 2, new investigational drug candidate at Eli Lilly and Company. The target compound was produced in the clinical pilot plant by the combination of two key steps: resolution of a morpholine amide intermediate to install the S-morpholino stereocenter in 35% yield and a high-yielding (89%) Grignard reaction to generate the title compound la, isolated as a mesylate salt. The Grignard reaction was found to proceed optimally when using a combination of I2 and DIBAL-H for the initiation. In addition, the Grignard reagent formation was monitored by ReactMax calorimetry, and proof-of-concept studies were completed, demonstrating that the Grignard step could potentially be run as a continuous process with magnesium recycling.

Dibenzyl Amine Compounds and Derivatives

Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

FLUORENE DERIVATIVE

This invention relates to a novel fluorene derivative having a characteristic structure in which guanidino group or the like functional group is linked to the fluorene structure via carbonyl group, or a salt thereof. The compound of the invention has an a

MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS

Compounds of the general formula (I) are inhibitors of the reuptake of norepinephrine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system.